New York, New York 10021

  • Lung Cancer


RATIONALE: Drugs used in chemotherapy, such as ABI-007, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I/II trial is studying the side effects and best dose of ABI-007 and to see how well it works in treating patients with stage IV non-small cell lung cancer.

Study summary:

OBJECTIVES: Primary - Determine the maximum tolerated dose and dose-limiting toxicity of paclitaxel (albumin-stabilized Nanoparticle formulation) (ABI-007) in patients with chemotherapy-naïve stage IV non-small cell lung cancer. - Determine the antitumor activity of this drug in these patients. - Determine the safety and tolerability of this drug in these patients. Secondary - Determine the time to disease progression in patients treated with this drug. - Determine duration of response in patients treated with this drug. - Determine survival of patients treated with this drug. OUTLINE: This is an open-label, dose-escalation study. - Phase I: Patients receive paclitaxel (albumin-stabilized Nanoparticle formulation) (ABI-007) IV on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of ABI-007 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. - Phase II: Patients receive ABI-007 as above at the MTD (determined in phase I). Patients are followed monthly for 6 months and then every 3 months for 1.5 years. PROJECTED ACCRUAL: A total of 64 patients will be accrued for this study.


DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed stage IV non-small cell lung cancer - Evidence of inoperable local recurrence or metastasis - Bone metastases or other nonmeasurable disease may not be only evidence of metastasis - Measurable disease documented radiographically - No evidence of active brain metastases or leptomeningeal involvement PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-1 OR - Karnofsky 80-100% Life expectancy - More than 12 weeks Hematopoietic - Absolute neutrophil count ≥ 1,500/mm^3 - Platelet count ≥ 100,000/mm^3 - Hemoglobin ≥ 9 g/dL Hepatic - AST and ALT ≤ 2.5 times upper limit of normal (ULN) - Bilirubin normal - Alkaline phosphatase ≤ 2.5 times ULN (unless due to bone metastases and there is no radiologic evidence of hepatic metastases) Renal - Creatinine ≤ 1.5 mg/dL Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective barrier contraception for 1 month before and during study participation - No prior allergy or hypersensitivity to study drug - No other concurrent active malignancy - No pre-existing peripheral neuropathy grade 1 or greater - No other concurrent clinically significant illness - No concurrent serious medical risk factor involving any of the major organ systems that would preclude study participation PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - No prior chemotherapy for metastatic disease - More than 4 weeks since prior cytotoxic chemotherapy - No concurrent doxorubicin - No other concurrent taxanes - No concurrent anthracyclines Endocrine therapy - Not specified Radiotherapy - At least 3 weeks since prior radiotherapy to a major bone marrow-containing area - More than 4 weeks since prior radiotherapy except to a non-target lesion - Prior radiotherapy to a target lesion allowed provided there has been clear progression of the lesion since completion of radiotherapy Surgery - Not specified Other - Prior epidermal growth factor-targeted therapy allowed - More than 4 weeks since prior investigational drugs - No concurrent enrollment in another clinical trial in which investigational drugs are administered or investigational procedures are performed - No concurrent treatment with any of the following: - Ritonavir - Saquinavir - Indinavir - Nelfinavir - No concurrent anticonvulsants - No other concurrent anticancer drugs - No other concurrent investigational drugs



Primary Contact:

Study Chair
Naiyer Rizvi, MD
Memorial Sloan-Kettering Cancer Center

Backup Contact:


Location Contact:

New York, New York 10021
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 30, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.